title: Nilotinib-induced interstitial lung disease.
abstract: Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosome-positive (Ph(+)) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph(+) CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.
authors.affiliation: Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer Center, Institute of Health Sciences, Gyeongsang National University School of Medicine, 90 Chilam-dong, Jinju, 660-702, Korea.
authors.forename: Se-Il
authors.initials: SI
authors.lastname: Go
authors.forename: Won Sup
authors.initials: WS
authors.lastname: Lee
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.forename: Jung Hun
authors.initials: JH
authors.lastname: Kang
authors.forename: Myung Hee
authors.initials: MH
authors.lastname: Kang
authors.forename: Jeong-Hee
authors.initials: JH
authors.lastname: Lee
authors.forename: Hoon-Gu
authors.initials: HG
authors.lastname: Kim
mesh_terms: D000368:Aged; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D057915:Drug Substitution; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008168:Lung / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D013902:Radiography, Thoracic; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D005938:Glucocorticoids; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone; D011505:Protein-Tyrosine Kinases; C498826:nilotinib